IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -180.76 Million SEK | -59.26% |
| 2022 | -113.1 Million SEK | -315.13% |
| 2021 | 52.57 Million SEK | 157.49% |
| 2020 | -91.45 Million SEK | 4.58% |
| 2019 | -95.84 Million SEK | -29.7% |
| 2018 | -73.89 Million SEK | -36.29% |
| 2017 | -54.21 Million SEK | -10.2% |
| 2016 | -49.19 Million SEK | -78.44% |
| 2015 | -27.57 Million SEK | -90.46% |
| 2014 | -14.47 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -9.52 Million SEK | 74.52% |
| 2024 Q3 | -36.71 Million SEK | -208.49% |
| 2024 Q1 | -37.36 Million SEK | -5.01% |
| 2023 Q2 | -44.87 Million SEK | 24.6% |
| 2023 Q4 | -35.57 Million SEK | 12.66% |
| 2023 FY | -180.13 Million SEK | -59.26% |
| 2023 Q3 | -40.73 Million SEK | 9.21% |
| 2023 Q1 | -59.5 Million SEK | -79.88% |
| 2022 Q3 | -23.92 Million SEK | 11.44% |
| 2022 Q2 | -27.01 Million SEK | 7.13% |
| 2022 Q1 | -29.08 Million SEK | -28.7% |
| 2022 FY | -113.1 Million SEK | -315.13% |
| 2022 Q4 | -33.08 Million SEK | -38.28% |
| 2021 Q2 | -26.52 Million SEK | -32.82% |
| 2021 FY | 52.57 Million SEK | 157.49% |
| 2021 Q4 | -22.6 Million SEK | -118.58% |
| 2021 Q1 | -19.96 Million SEK | -2.79% |
| 2021 Q3 | 121.66 Million SEK | 558.75% |
| 2020 Q2 | -26.1 Million SEK | -36.94% |
| 2020 Q3 | -26.86 Million SEK | -2.93% |
| 2020 Q4 | -19.42 Million SEK | 27.7% |
| 2020 FY | -91.45 Million SEK | 4.58% |
| 2020 Q1 | -19.06 Million SEK | 27.56% |
| 2019 FY | -95.84 Million SEK | -29.7% |
| 2019 Q4 | -26.31 Million SEK | -22.46% |
| 2019 Q3 | -21.48 Million SEK | 29.3% |
| 2019 Q2 | -30.39 Million SEK | -72.23% |
| 2019 Q1 | -17.64 Million SEK | 5.29% |
| 2018 Q1 | -15.85 Million SEK | -21.94% |
| 2018 FY | -73.89 Million SEK | -36.29% |
| 2018 Q4 | -18.63 Million SEK | -17.46% |
| 2018 Q2 | -23.54 Million SEK | -48.56% |
| 2018 Q3 | -15.86 Million SEK | 32.63% |
| 2017 Q1 | -9.88 Million SEK | 44.3% |
| 2017 Q2 | -10.64 Million SEK | -7.6% |
| 2017 Q3 | -20.68 Million SEK | -94.43% |
| 2017 Q4 | -12.99 Million SEK | 37.17% |
| 2017 FY | -54.21 Million SEK | -10.2% |
| 2016 Q1 | -14.03 Million SEK | 0.0% |
| 2016 FY | -49.19 Million SEK | -78.44% |
| 2016 Q3 | -10.6 Million SEK | -55.93% |
| 2016 Q2 | -6.8 Million SEK | 51.52% |
| 2016 Q4 | -17.75 Million SEK | -67.37% |
| 2015 FY | -27.57 Million SEK | -90.46% |
| 2014 FY | -14.47 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 27.399% |
| Ziccum AB (publ) | -21.56 Million SEK | -738.428% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1002.158% |
| BioArctic AB (publ) | 252.64 Million SEK | 171.55% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -21292.308% |
| Mendus AB (publ) | -100.65 Million SEK | -79.598% |
| Genovis AB (publ.) | 54.22 Million SEK | 433.367% |
| Intervacc AB (publ) | -93.57 Million SEK | -93.168% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1065.324% |
| Active Biotech AB (publ) | -46.48 Million SEK | -288.876% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1103.748% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -226.191% |
| Aptahem AB (publ) | -10.1 Million SEK | -1688.909% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 43.776% |
| Kancera AB (publ) | -65.04 Million SEK | -177.92% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -34.281% |
| Fluicell AB (publ) | -26.87 Million SEK | -572.514% |
| Saniona AB (publ) | -81.06 Million SEK | -122.988% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -1361.2% |
| Biovica International AB (publ) | -126.07 Million SEK | -43.381% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -325.279% |
| AcouSort AB (publ) | -17.48 Million SEK | -933.711% |
| Xintela AB (publ) | -57.23 Million SEK | -215.813% |
| Abliva AB (publ) | -96.54 Million SEK | -87.228% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 44.346% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -5057.347% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1036.744% |
| Amniotics AB (publ) | -29.07 Million SEK | -521.762% |
| 2cureX AB (publ) | -36.36 Million SEK | -397.112% |
| CombiGene AB (publ) | -36.3 Million SEK | -397.904% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -1134.734% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 52.974% |
| Camurus AB (publ) | 532.35 Million SEK | 133.956% |
| Corline Biomedical AB | -1.78 Million SEK | -10009.899% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -333.666% |
| I-Tech AB | 24.43 Million SEK | 839.779% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 77.075% |
| Cyxone AB (publ) | -21.66 Million SEK | -734.518% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -70.589% |
| Biosergen AB | -27.26 Million SEK | -562.993% |
| Cantargia AB (publ) | -290.01 Million SEK | 37.671% |
| NextCell Pharma AB | -43.17 Million SEK | -318.708% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -0.0% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -957.335% |
| Nanologica AB (publ) | -69.96 Million SEK | -158.372% |
| SynAct Pharma AB | -224.49 Million SEK | 19.48% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -309.193% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -654.625% |
| LIDDS AB (publ) | -40.67 Million SEK | -344.424% |
| Lipum AB (publ) | -37.25 Million SEK | -385.223% |
| BioInvent International AB (publ) | -369.94 Million SEK | 51.137% |
| Alzinova AB (publ) | -16.52 Million SEK | -994.087% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 28.677% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -2727.436% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -57.087% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -797.587% |
| Simris Alg AB (publ) | -36.63 Million SEK | -393.422% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -23.333% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 41.769% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -62.978% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -1462.9% |